Isfahan University of Medical Sciences

Science Communicator Platform

Share By
Guillain-Barre Syndrome (Gbs) As a Covid-19 Complication: A Multicenter Study Conducted Throughout the 2-Year Pandemic Publisher

Summary: What predicts worse Guillain-Barre after COVID-19? In 45 patients, early neurological onset and axonal injury tracked disability and poorer response. #Neurology #COVID19

Behnaz A ; Mohsen K ; Najafi M A ; Keivan B ; Fariborz K ; Negin F ; Majid G
Authors

Source: Advanced Biomedical Research Published:2026


Abstract

Background: – Several studies have been published on the coexistence of Guillain-Barre syndrome (GBS) and COVID-19, raising the question of whether SARS-CoV-2 plays a role in GBS pathogenesis or is just a coincidence. In this research, we discuss GBS characteristics in COVID-19 patients during the pandemic. Material and Methods: – This cross-sectional, multi-center study was performed on patients who were hospitalized in one of two GBS referral hospitals in Isfahan Providence between March 2020 to March 2022. All confirmed GBS and COVID-19 patients with no other known risk factor for GBS and no more than 28 days of COVID-19 treatment were entered into the trial. Results: – Totally, 45 patients were collected. The most prevalent EDX pattern was AIDP (57.8%). As compared to demyelinating injuries, axonal injuries were significantly more associated with lung involvement (P value: 0.022), higher GBS disability score (P value: 0.034), poorer response to treatment (P value: 0.021), higher serum inflammatory level, and older onset (P value: 0.013). The average period between the onset of COVID-19 and the onset of GBS symptoms was 18.07 ± 9.88 days. 46.3% of patients developed GBS within the first two weeks of COVID-19, a condition known as a para-infection. The axonal injury was significantly more prevalent in these individuals (P value: 0.045). Conclusion: – An earlier onset of neurological symptoms and para-infection conditions is associated with an increase in the frequency of axonal-type variations and, as a result, a poor prognosis. The majority of evidence in COVID-19-related GBS patients points to an autoimmune process. © 2026 Advanced Biomedical Research
Other Related Docs
8. Characteristics of Covid-19 in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
18. T-Cell Immunophenotyping in Covid-19 Pneumonia, Journal of Research in Medical Sciences (2021)